Table 1. . Summary of selected prospective studies assessing stereotactic body radiation therapy in NSCLC.
| Study/Investigator(s) [Ref.] | Publication year | Number of patients | Radiation dose/fractionation (Gy) | BED10 (Gy) | Local control (%) | Overall survival (%) | Toxicity (≥ Grade 3) |
|---|---|---|---|---|---|---|---|
| Kyoto University, Japan/Nagata [17] | 2005 | 45 | 48/4 | 105.6 | 98% | Stage IA at: 1 year: 92% 3 year: 83% Stage IB at: 1 year: 82% 3 year: 72% |
None |
| Air Force General Hospital, China/Xia [19] | 2006 | 43 | 50/5 | 100 | 95% | 1 year: 100% 3 year: 91% |
2% (n = 1); pneumonitis |
| Nordic Group/Baumann & Nyman [29] | 2009 | 57 | 66/3 | 211.2 | 92% | 3 year: 60% | 30% (n = 17) |
| RTOG 0236/Timmerman [31] | 2010 | 55 | 54/3 | 151.2 | 93% | 5 year: 40 % | 27% (n = 15) |
| Princess Margaret/Taremi [33] | 2012 | 108 | 60/3 (n = 31) 54/3 (n = 20) 48/4 (n = 43) 60/8 (n = 9) 50/10 (n = 11) |
180 151.2 105.6 105 75 |
100% 95% 95% 78% 82% |
1 year: 84% 4 year: 30% |
15% (n = 16) |
| RTOG 0915/Videtic [34] | 2013 | 84 | 34/1 (n = 39) 48/4 (n = 45) |
149.6 105.6 |
97% 98% |
2 year: 61.3% 2 year: 77.7% |
10% (n = 4) 13% (n = 6) |
| EORTC-LungTech/Adebahr [35] | 2015 | 39 | 60/8 | 105 | Not yet reported | Not yet reported | Not yet reported |
| SPACE/Nyman & Hallqvist [36] | 2016 | 49 | 66/3 | 211.2 | 86% | 1 year: 81% 3 year: 54% |
14% (n = 7) |
BED: Biologically effective dose; RTOG: Radiation Therapy Oncology Group.